Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B
Buti, Maria (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Stepanova, Maria (Center for Outcomes Research in Liver Disease, Washington, DC, USA)
Palom, Adriana (Hospital Universitari Vall d'Hebron)
Riveiro Barciela, Mar (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Nader, Fatema (Center for Outcomes Research in Liver Disease, Washington)
Roade, Luisa (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Esteban, Rafael (Esteban Mur) (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Younossi, Zobair (Betty and Guy Beatty Center for Integrated Research)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Health-related quality of life (HRQoL) determined by patient-reported outcomes (PROs) is impaired in chronic hepatitis B (CHB) and C patients, but there are no data regarding patients with chronic hepatitis D (CHD). The aim of this study was to assess PRO scores in untreated patients with CHD and compare them with those obtained for patients with CHB. Patients with CHD completed 3 PRO instruments (Chronic Liver Disease Questionnaire [CLDQ], Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F], and Work Productivity and Activity Impairment [WPAI]), and the results were compared with those of patients mono-infected with CHB. In total, 125 patients were included: 43 with CHD and 82 with CHB. Overall, baseline PROs showed differences between both groups. Several assessments, such as the worry score from CLDQ (p = 0. 0118), functional well-being from FACIT-F (p = 0. 0281), and activity impairment from WPAI (p = 0. 0029) showed a significant trend to worse scores in patients with CHD than with CHB. In addition, the linear regression model supports the finding that having CHD as opposed to having CHB was a predictor of a higher worry score (CLDQ) and a higher activity impairment (WPAI). In this first assessment in CHD, PROs recorded in patients with CHD showed a significant impairment in some domains of HRQoL questionnaires in comparison with those with CHB. Studies in larger cohorts with lengthier follow-up are needed to fully assess patient-reported quality of life over the course of CHD. Chronic hepatitis D (CHD) is a viral disease that causes rapid evolution to liver cirrhosis, amongst other severe complications, when compared to patients with chronic hepatitis B (CHB). Health-related quality of life in chronic hepatitis C and CHB has been reported widely, but no studies have been performed on patient-reported outcomes in patients with CHD. Results showed that CHD patients reported worse outcomes in psychological domains such as worry and emotional well-being, as well as in physical domains such as abdominal symptoms, physical well-being, and activity impairment in comparison with patients with CHB.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Viral hepatitis ; Health-related quality of life ; Chronic Liver Disease Questionnaire ; Functional Assessment of Chronic Illness Therapy-Fatigue ; Work Productivity Activity Impairment ; ALT, alanine aminotransferase ; APRI, AST to platelet ratio index ; AST, aspartate aminotransferase ; CHB, chronic hepatitis B ; CHC, chronic hepatitis C ; CHD, chronic hepatitis D ; CLDQ, Chronic Liver Disease Questionnaire ; DAA, direct-acting antivirals ; EMA, European medicines agency ; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue ; FIB-4, Fibrosis-4 ; HRQoL, health-related quality of life ; IFN, interferon ; LLOD, lower limit of detection ; LLOQ, lower limit of quantification ; NAs, nucleos(t)ide analogues ; Pegifn, pegylated interferon ; PROs, patient-reported outcomes ; WPAI, Work Productivity and Activity Impairment
Published in:	JHEP Reports, Vol. 3 (march 2021) , ISSN 2589-5559

DOI: 10.1016/j.jhepr.2021.100280
PMID: 34041466

8 p, 251.6 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles